Effect of spironolactone on C-reactive protein levels in patients with heart disease

International Journal of Cardiology

Volumn 117, Issue 2, 2007, Pages 282-284

  Godfrey, Valerie ^a   Farquharson, Colin A J ^a   Macdonald, John E ^a   Yee, Kok Meng ^a   Struthers, Allan D ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Aldosterone; C reactive protein; Inflammation; Spironolactone

Indexed keywords

ALDOSTERONE; C REACTIVE PROTEIN; PLACEBO; SPIRONOLACTONE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HEART FAILURE; HUMAN; INFLAMMATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME;

ALDOSTERONE ANTAGONISTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; HEART FAILURE, CONGESTIVE; HUMANS; RANDOMIZED CONTROLLED TRIALS; SPIRONOLACTONE;

EID: 33947424811     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.05.069     Document Type: Article

References (8)

1. Rocha R., Rudolph A.E., Frierdich G.E., et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 283 (2002) 1802-1810
2. Rocha R., and Williams G.H. Rationale for the use of aldosterone antagonists in congestive heart failure. Drugs 62 (2002) 723-731
3. Blasi E.R., Rocha R., Rudolph A.E., Blomme E.A., Polly M.L., and McMahon G.E. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 63 (2003) 1791-1800
4. Morrow D.A., and Ridker P.M. C-reactive protein, inflammation, and coronary risk. Med Clin North Am 84 (2000) 49-161
5. Macdonald J.E., Kennedy N., and Struthers A.D. Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart 90 (2005) 765-770
6. Yee K., Pringle S.D., and Struthers A.D. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol 37 (2001) 1800-1807
7. Farquharson C.A., and Struthers A.D. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensinI/angiotensinII conversion in patients with chronic heart failure. Circulation 101 (2000) 594-597
8. Albert M.A., and Ridker P.M. The role of C-reactive protein in cardiovascular disease risk. Curr Cardiol Rep 1 (1999) 99-104